Adelaide Research & Scholarship: Search

Search

Results 1-5 of 5 (Search time: 0.001 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2021	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer	Lin, H.-M.; Huynh, K.; Kohli, M.; Tan, W.; Azad, A.A.; Yeung, N.; Mahon, K.L.; Mak, B.; Sutherland, P.D.; Shepherd, A.; Mellett, N.; Docanto, M.; Giles, C.; Centenera, M.M.; Butler, L.M.; Meikle, P.J.; Horvath, L.G.
	2022	Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming	Wu, Y.; Clark, K.C.; Nguyen, E.V.; Niranjan, B.; Horvath, L.G.; Taylor, R.A.; Daly, R.J.
	2023	Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts	Wu, Y.; Clark, K.C.; Niranjan, B.; Chüeh, A.C.; Horvath, L.G.; Taylor, R.A.; Daly, R.J.
	2021	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP	Stockler, M.R.; Martin, A.J.; Davis, I.D.; Dhillon, H.M.; Begbie, S.D.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; et al.
	2020	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)	Scheinberg, T.; Kench, J.; Stockler, M.; Mahon, K.L.; Sebastian, L.; Stricker, P.; Joshua, A.M.; Woo, H.; Thanigasalam, R.; Ahmadi, N.; Centenera, M.M.; Butler, L.M.; Horvath, L.G.